In a significant move to strengthen its presence in India’s rapidly growing medical devices sector, Jashvik Capital backed Futura Medtech has announced a strategic investment in Bengaluru based Rivarp Medical. The deal marks the third investment under the Futura Medtech platform, reinforcing its ambition to build a multi category medtech ecosystem with both domestic strength and global reach.
Rivarp Medical, founded in 2016, specializes in manufacturing medical devices and implants across key therapeutic areas such as orthopaedics, neurosurgery, and interventional cardiology. This investment expands Futura’s portfolio into these high growth segments, complementing its existing focus on surgical consumables and devices.
The acquisition aligns with Jashvik Capital’s broader strategy of creating a scalable and integrated medtech platform. Prior investments in Dolphin Sutures (2024) and Suture Planet (2025) have already laid the foundation, and Rivarp’s addition is expected to further strengthen product diversity and innovation capabilities.
Rivarp brings strong advantages to the platform, including in house manufacturing, a differentiated product portfolio, and international regulatory approvals such as EU MDR and US FDA certifications. Its products are distributed across India and global markets through a network of over 100 channel partners, offering Futura immediate access to expanded distribution channels.
The move comes at a time when India’s medical devices industry is witnessing sustained double digit growth, driven by rising healthcare demand, increased domestic manufacturing, and growing export opportunities. With this investment, Futura Medtech aims to leverage synergies in innovation, manufacturing, and distribution to scale its operations and deliver high quality medical solutions worldwide.
“Medical devices and consumables are a large and fast growing opportunity… we aim to drive synergies in innovation, manufacturing, and distribution.”
By
HB Team
